<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690387</url>
  </required_header>
  <id_info>
    <org_study_id>CL-COV-P02-ID</org_study_id>
    <nct_id>NCT04690387</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection</brief_title>
  <official_title>Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aivita Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PT AIVITA Biomedika Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indonesia Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aivita Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells&#xD;
      previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent&#xD;
      COVID-19 in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects eligible for treatment will be those who at baseline, are not actively infected with&#xD;
      SARS-CoV-2, have no evidence of prior infection with SARS-CoV- 2 based on serologic testing,&#xD;
      and give informed consent for a vaccination with AV-COVID-19. The patient population will&#xD;
      include the elderly and others at higher risk for poor outcomes after COVID-19 infection. For&#xD;
      this reason, individuals will not be excluded solely on the basis of age, body mass index,&#xD;
      history of hypertension, diabetes, cancer, or autoimmune disease.&#xD;
&#xD;
      After enrolling for screening, subjects will undergo a nasal swab test to exclude active&#xD;
      COVID-19 infection and a rapid test for anti-coronavirus antibodies to exclude pre-existing&#xD;
      anti-SARS-CoV-2 antibodies. 50 mL of blood will be collected, from which peripheral blood&#xD;
      monocytes will be isolated and differentiated into DC before incubation with SARS-CoV-2&#xD;
      S-protein, during which time the protein is digested into 9 to 25 amino acid peptide&#xD;
      sequences presented on the dendrites of DC in conjunction with histocompatibility class I and&#xD;
      class II molecules. Safety and quality testing will be performed on a small quantity of the&#xD;
      batch, and the remaining AV-COVID-19 will be cryopreserved for shipping to the treatment&#xD;
      site.&#xD;
&#xD;
      Once the Study Drug is ready, if eligible, the subject will be seen at Study Week-0 for&#xD;
      treatment. Prior to injection of the Study Drug, a nasal swab test will be collected to&#xD;
      confirm that they are still negative for COVID-19, and blood will be drawn to determine&#xD;
      baseline levels of anti-SARS-CoV-2 antibodies. At the treatment site, the product will be&#xD;
      thawed and admixed with saline or (saline with GM-CSF), and within 5 hours of thawing, will&#xD;
      be injected SC via a 25- gauge needle&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (safety)</measure>
    <time_frame>1 week</time_frame>
    <description>Collection of adverse event incidence and severity in all treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish optimal dose formulation</measure>
    <time_frame>1 month</time_frame>
    <description>Measurement of antibodies in subject blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of detection of antibodies against SARS-CoV-2</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of antibodies in subject blood</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>0.1 mg antigen, 0 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 0.1 mg antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.33 mg antigen, 0 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 0.33 mg antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg antigen, 0 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 1.0 mg antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 0.1 mg antigen, admixed with 250 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.33 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 0.33 mg antigen, admixed with 250 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 1.0 mg antigen, admixed with 250 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg antigen, 500 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 0.1 mg antigen, admixed with 500 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.33 mg antigen, 500 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 0.33 mg antigen, admixed with 500 mcg GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg antigen, 500 mcg GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells previously incubated with 1.0 mg antigen, admixed with 500 mcg GM-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AV-COVID-19</intervention_name>
    <description>Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein</description>
    <arm_group_label>0.1 mg antigen, 0 mcg GM-CSF</arm_group_label>
    <arm_group_label>0.1 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>0.1 mg antigen, 500 mcg GM-CSF</arm_group_label>
    <arm_group_label>0.33 mg antigen, 0 mcg GM-CSF</arm_group_label>
    <arm_group_label>0.33 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>0.33 mg antigen, 500 mcg GM-CSF</arm_group_label>
    <arm_group_label>1.0 mg antigen, 0 mcg GM-CSF</arm_group_label>
    <arm_group_label>1.0 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>1.0 mg antigen, 500 mcg GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>GM-CSF as an adjuvant</description>
    <arm_group_label>0.1 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>0.1 mg antigen, 500 mcg GM-CSF</arm_group_label>
    <arm_group_label>0.33 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>0.33 mg antigen, 500 mcg GM-CSF</arm_group_label>
    <arm_group_label>1.0 mg antigen, 250 mcg GM-CSF</arm_group_label>
    <arm_group_label>1.0 mg antigen, 500 mcg GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older, relatively good health, negative for pre-existing SARS-CoV-2&#xD;
             antibodies, negative for SARS-CoV-2 infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active COVID-19 infection by PCR testing, pre-existing SARS-CoV-2 antibodies,&#xD;
             pregnant, known hypersensitivity to GM-CSF, known immune deficiency disease, on active&#xD;
             treatment with immunosuppressive agent or corticosteroid, participated in previous&#xD;
             COVID-19 trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O Dillman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aivita Biomedical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rumah Sakit Umum Pusat Dr. Kariadi</name>
      <address>
        <city>Semarang</city>
        <state>Jawa Tengah</state>
        <zip>50244</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

